Optiray (Ioversol)

Ioversol’s iodine atoms absorb X‑ray photons strongly, increasing the radiodensity of the blood and extracellular fluid where it is distributed. This creates a contrast between enhanced structures and surrounding tissues, allowing imaging systems to differentiate anatomical details more clearly.

The dose of Optiray is individualized by the prescribing physician based on the specific imaging study, patient weight, renal function, and the required level of contrast enhancement. The healthcare professional determines the appropriate volume and concentration for each case.

Optiray is classified as pregnancy category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It should be used only if the diagnostic benefit justifies potential risk. Limited data are available for breastfeeding, so caution is advised.

To order Optiray, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Optiray (ioversol) is a non‑ionic, low‑osmolality iodinated contrast medium, offering a favorable safety profile compared with older high‑osmolality agents. It provides comparable image quality to other low‑osmolality agents such as iohexol or iopamidol, while generally causing fewer adverse reactions.

Optiray should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze the solution or shake it vigorously. Keep the vial in its original packaging until use to maintain sterility and stability.

Optiray is administered as an injectable solution via intravenous or intra‑arterial injection, depending on the imaging protocol. The injection is typically performed by a trained radiology or nursing professional using a power injector or manual bolus, following aseptic technique.

The most serious risks include severe allergic reactions (anaphylaxis), contrast‑induced nephropathy leading to renal impairment, and cardiovascular events such as severe hypotension or arrhythmias. Immediate medical attention is required if any of these reactions occur.

Optiray should be avoided in patients with a known hypersensitivity to ioversol or other iodinated contrast agents, those with uncontrolled severe renal insufficiency, and individuals with a history of severe thyroid disorders related to iodine exposure. Clinical judgment is essential for each patient.